Bliss GVS Pharma LimitedNSE: BLISSGVS

BLISSGVS: Revenue up, net profit down; subsidiary sale and dividend declared, restructuring ahead

· Issued by Bliss GVS Pharma Limited

Revenue grew year-over-year, but consolidated net profit declined due to lower margins and exceptional items. Board approved sale of a step-down subsidiary and asset, and recommended a final dividend, with restructuring expected to impact H1 FY26.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Bliss GVS Pharma Limited on 6ix

Earlier from Bliss GVS Pharma

Later from Bliss GVS Pharma

All Bliss GVS Pharma news releases